Since the study began in January 2007, the Gliogene Consortium has screened over 13,000 patients' family histories and discovered 850 families with two or more relatives with reported gliomas. Over 3,000 glioma patients and their relatives are participating in the study.

To date, we have completed genetic analysis on 70 families with two or more cases of glioma verified through medical records or pathology reports. Out of these families, 46 are from the United States, 17 are from Denmark and Sweden, and seven are from Israel.

In these 70 families, the average diagnosis age of the proband (the participant who initially enrolled in Gliogene) is 46.9 for United States families, 52.1 for Danish and Swedish families, and 37.8 for Israeli families. The diagnosis age ranges from one to 80 years old. Out of these families, 40 had two cases of glioma, 20 had three cases of glioma, five had four cases of glioma reported. 

Glioma types vary in the families we have recruited. There have been no consistent patterns of glioma type among affected family members.

We analyzed 101 glioma patient samples from enrolled families and found no evidence of p16INK$A.p14ARF or p53 mutations. Individuals with p16 mutations may have a higher risk for pancreatic cancer and melanoma, and individuals with p53 mutations may be more susceptible to cancer development and Li-Fraumeni syndrome (Robertson, et al.  Fam Cancer. 2010 Sep; 9(3): 413-21).